1 Burlington Road
Dublin 4, Ireland
Alkermes is a leader in innovative medicines that address the unmet needs and challenges of people living with debilitating diseases. As a fully integrated global biopharmaceutical company, Alkermes applies our scientific expertise, proprietary technologies and global resources to develop products that are designed to make a meaningful difference in the way patients manage their disease. Through our proven scientific, development and manufacturing capabilities, Alkermes is uniquely positioned to be an engine of innovative treatments for major clinical conditions specifically focused on central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis.
The success of our approach is reflected in:
- Proven expertise reflected in a diversified commercial product portfolio;
- A pipeline of novel product candidates focused on CNS diseases in clinical development;
- Proprietary science and technology that leads to the discovery of new, patentable medicines; and
- Our commitment to developing new treatment options for major diseases with patient needs in mind.
Richard Pops serves as Chairman and Chief Executive Officer of Alkermes. He joined Alkermes as CEO in 1991. Under his leadership, Alkermes has grown from a privately held company with 25 employees to an international, publicly traded biopharmaceutical company with more than 1,600 employees. Alkermes has a diversified commercial product portfolio and a substantial clinical pipeline of central nervous system (CNS) product candidates. Mr. Pops currently serves on the Value and Coverage Advisory Council of FasterCures, as well as on the Board of Directors of Neurocrine Biosciences, Acceleron Pharma, Epizyme, the Biotechnology Industry Organization (BIO), the Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Health Council.
A Portfolio of Vital Products
Alkermes’ diverse product portfolio reflects our powerful expertise in the development of innovative patient-inspired solutions. Our products are based on proprietary science and technology that provide unique treatment options for patients with debilitating diseases. In particular, Alkermes is focused on drug development for central nervous system (CNS) diseases, a therapeutic area where we have a proven track record. Our aim is to develop new medicines that make significant advances for chronic CNS conditions that affect millions of patients, such as schizophrenia, major depressive disorder and multiple sclerosis. Click here to learn about our strong pipeline of innovative product candidates.
Research & Development Overview:
Along with our deep scientific expertise and unique patient-inspired focus, our proprietary technological and manufacturing capabilities form the foundation for Alkermes’ commitment to science with a purpose. Not coincidentally, these are also the driving forces behind our innovations. The result? A diversified product portfolio that’s enabled us to deliver value to patients and establish ourselves as a leader in the global biopharmaceutical industry.
Our R&D Approach:
Our patient-inspired R&D approach is grounded in a thoughtful focus on the real-world challenges that patients with central nervous system (CNS) disorders face on a daily basis. Through this lens, we seek to develop new medications that offer significant medical benefits, including improved efficacy, safety and ease-of-use for both patients and caregivers—all with the ultimate goal of reducing suffering and improving treatment outcomes for millions.
Technologies That Give Us An Edge:
Alkermes’ proprietary technologies and deep expertise gives us the edge in developing innovative medicines with therapeutically advantageous properties. Our ability to combine our understanding of unmet patient needs with our cutting edge tools and capabilities enables us to target CNS diseases in unique ways, resulting in drugs that have distinct value in their markets and for patients.
Our suite of long-acting injectable technologies enables the gradual release into the body of small molecules as well as complex macromolecules at a controlled rate over a specific period of time. By enabling patients to take medications less frequently, these technologies create drugs that can be especially beneficial in treating CNS diseases such as psychiatric disorders, in which medication compliance is closely correlated with improved outcomes. Our long-acting technology platforms include Medisorb, LinkeRx and NanoCrystal.
Alkermes’ clinical trials are important milestones on the path to discovering new therapies that may address significant unmet medical needs for patients. Keeping physicians, patients and caregivers up-to-date about such studies is one of our top priorities. For information about clinical trials using Alkermes’ products or development candidates, sponsored by Alkermes or other institutions, consult the National Institute of Health website, www.clinicaltrials.gov, which contains a searchable database.
Alkermes Corporate Giving:
Alkermes underscores its commitment to central nervous system (CNS) disorders, such as schizophrenia, depression and addiction, by supporting educational, healthcare-related, and public policy events through sponsorships, charitable and educational grants programs, as well as through investigator initiated trials. In addition, Alkermes fosters and maintains collaborative relationships with health-related and public policy organizations through corporate memberships.
Investigator Initiated Trials (IIT):
Through our Investigator Initiated Trial (IIT) program, Alkermes seeks to support investigator research designed and conducted by independent physicians and scientists. Since the beginning of the IIT program in 2008, Alkermes has supported over 30 trials which have ranged in indication from use in alcohol and opioid dependent populations to methamphetamine and cocaine use. Alkermes typically provides either study drug and/or placebo to those IIT programs it supports, but has in limited instances also provided financial support as well. The vast majority of the research we support is based in the U.S. with experienced researchers that have secured funding throughout a government agency.
Alkermes Education Grants:
Alkermes is interested in contributing to independent education through grants. Our particular focus this year includes educational activities with pragmatic approaches to improve patient care and public health in the domains of schizophrenia, alcohol and opioid dependence, and depression. We expect to contribute to a better understanding of the treatment in a broader sense including psychosocial methods as well as medications. Alkermes’ grant funds may not be used to support overhead expenses of the applicant or for any other institution affiliated with the applicant.
Examples of appropriate requestors of education grants include, but are not limited to:
- Accredited Educational Providers
- Medical or Professional Associations or Societies
- Community Health Centers, Hospitals, Health Systems or Academic Medical Centers
- Schools of Nursing or Pharmacy
- Disease Related Organizations
- Patient Advocacy Non-profit Groups
- Medical Education Companies
- Corporate Profile
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.
Time of Growth:
It’s an exciting time to be a member of the Alkermes team. The pace is fast, the environment is dynamic and the ideas are inspired. The reward of helping to make a difference in the lives of millions of people encourages a culture of compassion and awareness. If you are interested in contributing to our team and helping us reach our goals, please take a look at our current job openings.
Krebs Biochemicals & Industries Limited
click above to visit
this company / organization